CLOs on the Move

Everest Clinical Research

www.ecrscorp.com

 
Everest Clinical Research ("Everest") is a full-service contract research organization (CRO) providing a broad range of expertise-based clinical research services to worldwide pharmaceutical, biotechnology, and medical device industries. We serve some of the best-known companies and work with many of the most advanced drugs, biologics, and medical devices in development today.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.ecrscorp.com
  • 675 Cochrane Drive East Tower, 4th Floor
    Markham, ON CAN L3R 0B8
  • Phone: 905.752.5222

Executives

Name Title Contact Details

Similar Companies

Interspond

Interspond is a Trial Management Organization (TMO) that works with a network of multi therapeutic sites across the country to facilitate clinical and pharmaceutical research and trials.

Fifty 50 Pharmacy

Fifty 50 Pharmacy is a Carrollton, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Organon

Organon is a West Orange, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Stat-Tech Services

Stat-Tech Services is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.